Nov 13, 2019
MediSieve in Sunday Telegraph and the Mirror
Founder and CEO, Dr George Frodsham, speaks to the Telegraph on the birth and journey of MediSieve.
You may have seen us featured in the Telegraph on Sunday 10 November.
Here, Dr Frodsham, divulges how he came up with the idea while studying how magnetic nanoparticles can be made to bind to cells in the body, to allow, for example those cells to show up on scanners.
Read the full article here.
We were also fortunate enough to have this article featured in The Mirror.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: